Scientific Work
Scientific Work information about Prof. Dr. Ibrahim Benter.
World-Class Discovery & Clinical Trials
Clinical trials conducted on humans in the US for Angiotensin-(1-7), defined by Prof. Dr. Ibrahim Benter in 1993.
Angiotensin-(1-7) Discovery
Prof. Dr. Ibrahim Benter revolutionized the medical world in 1993 by defining the "angiotensin-(1–7)" molecule. This vital peptide acts as a protective, anti-inflammatory, and vasoprotective hormone in the body, opening new horizons in the treatment of hypertension, diabetes, kidney, and heart diseases. Benter is among the most cited scientists globally for his work in this field.
US Clinical Trials (ClinicalTrials.gov)
The synthetic form of the molecule defined by Benter, TXA127 (Angiotensin-1-7), is being tested in clinical trials at the US National Institutes of Health (NIH) and American hospitals for the treatment of various diseases:
Post-Ischemic Stroke Recovery
Evaluating the safety and efficacy of TXA127 in restoring brain functions and mobility in post-stroke patients (Phase 2).
View Clinical TrialSevere COVID-19 & Preventing Kidney Injury
Investigating TXA127 to prevent acute kidney injury and multi-organ failure in patients with severe COVID-19.
View Clinical TrialCord Blood Transplant & Hematopoietic Support
Evaluating TXA127 to enhance blood cell recovery and reduce chemotherapy complications in transplant patients.
View Clinical Trial